Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This review discusses the role of the JAK-STAT pathway in autoimmune skin diseases and suggests potential therapeutic benefits of JAK inhibitors, but reports no new experimental results.

JAK inhibitors and platelet-rich plasma show promise for treating alopecia areata.

This study found that neonatal mice without the urokinase-type plasminogen activator (uPA) gene had reduced epidermal proliferation rates, suggesting uPA's involvement in promoting keratinocyte proliferation.

This study highlights the recent FDA approval of baricitinib as the first on-label treatment for severe alopecia areata, whereas previous treatments were off-label therapies like systemic steroids and immunosuppressants.

In this study, treatment with human follicular keratinocyte-conditioned media improved the trichogenicity of cultured dermal cells by activating key signalling pathways, suggesting its potential use in cell therapy for hair loss.

This review discusses how JAK inhibitors, like tofacitinib and baricitinib, show promise in improving conditions like lichen planopilaris and frontal fibrosing alopecia by reducing severity scores and enhancing hair regrowth, though further research on safety and personalized approaches is needed.

Early diagnosis, innovative treatments, and considering systemic conditions are crucial in dermatological care.

This review discusses the role of Janus-kinase inhibitors in treating severe atopic dermatitis and alopecia areata, presenting case studies that show their efficacy and calling for further research on long-term effectiveness and safety.

In this study, JAK inhibitors for treating alopecia areata and atopic dermatitis were generally well tolerated in a real-world setting, with most adverse events being mild or moderate and rare serious cases resembling the general population incidence.

This case report suggests that starting selective Janus kinase 1 inhibition may improve alopecia in a patient with rheumatoid arthritis who was not responding to TNF-α inhibitor therapy and corticosteroids.

A JAK1 variant causes hair loss, skin issues, and thyroid disease, but treatment with a specific inhibitor can help.

Significant hair regrowth doesn't always mean complete hair recovery in alopecia areata.

This review summarized the latest knowledge suggesting that Janus kinase inhibitors may have therapeutic potential for treating skin diseases like atopic dermatitis and psoriasis, especially when conventional therapies do not work.

In this case report, researchers observed that a 35-year-old male with alopecia universalis achieved full regrowth of scalp, eyebrow, and facial hair with oral upadacitinib treatment after previous therapies failed to provide lasting relief.

JAK inhibitors are generally safe for treating alopecia areata.

This review highlights the potential for JAK inhibitors to effectively treat inflammatory and autoimmune skin diseases by targeting the JAK-STAT signaling pathway, advocating for an integrated approach to enhance targeted therapy.

This review discusses the role of JAK inhibitors in treating atopic dermatitis, alopecia areata, and vitiligo, highlighting their effectiveness and safety considerations but stressing the need for further research on long-term safety and patient selection.

This review examines various pharmacological options for managing alopecia areata, highlighting the effectiveness of corticosteroids for mild to moderate cases and promising results from JAK inhibitors like baricitinib for more severe forms, with additional benefits from minoxidil and potential from other treatments.

This review found that oral JAK inhibitors, used off-label in various inflammatory skin disorders, often resulted in rapid and sustained clinical improvements with acceptable safety over several months, although the evidence is drawn from case-based reports.

This study found that low-dose oral minoxidil increased terminal hair density in patients with androgenetic alopecia, providing an alternative dosage comparable to the topical 5% solution.

This case series observed that five Black pediatric patients with moderate to severe alopecia areata showed significant hair regrowth and minimal disease activity after treatment with topical JAK inhibitors, vitamin D supplementation, and antihistamines, with additional therapies in some cases.

This study reviewed therapies for alopecia areata and suggests that Janus kinase inhibitors, such as baricitinib and upadacitinib, show promise in treating both alopecia areata and associated immune-mediated inflammatory diseases.

This study observed that early treatment with ritlecitinib in patients with alopecia areata, especially when severity is low, led to more favorable responses, and continued improvement was seen up to 24 months, offering guidance on treatment timing and duration.

This study reviewed literature and assessed clinical data on treating alopecia areata linked with atopic diseases, finding that therapies like dupilumab, phototherapy, and JAK inhibitors may address overlapping symptoms, suggesting a focus on reducing pharmacological burden and enhancing quality of life.

This literature review found that Janus kinase inhibitors may help achieve remission in patients with refractory primary neutrophilic cicatricial alopecias, though data is limited to small case series and reports.

In this study, JAK inhibitors significantly improved outcomes for patients with both atopic dermatitis and alopecia areata, while dupilumab was linked to worsening alopecia in some cases.

In this case report, a nearly 12-year-old boy with alopecia universalis and atopic dermatitis experienced full hair regrowth and improved dermatitis following treatment with upadacitinib, a JAK 1 inhibitor, showing notable positive effects on his psychological well-being and family.

This study reports that JAK inhibitors were effective in inducing remission in ulcerative colitis patients and presented an acceptable safety profile with a range of manageable side effects.

This research highlights that while JAK inhibitors are effective for various inflammatory conditions, studies raise concerns about increased risks of venous and arterial thromboembolism, and cancer, particularly with tofacitinib and baricitinib, leading to European guidelines recommending caution in high-risk patients.

In 2021, JAMA Dermatology published significant findings on skin conditions post-COVID vaccination, melanoma surveillance, atopic dermatitis treatments, and confirmed that sun protection does not harm bone health.